A Phase 1 interventional study of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT) and 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine in Pneumococcal Infections, Streptococcal Infections and Bacterial Infections, sponsored by CanSino Biologics Inc.. Completed at 1 site in China. Open to participants aged 6 Weeks and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-31.
Sponsored by CanSino Biologics Inc. · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Pneumococcal Infections with a site in China — 6 open to participants now, 9 under way, 4 of them phase 3. Pneumococcal Infections · China.
Among the 36 studies in Pneumococcal Infections with a site in China, this one is the 25th largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2020, is one of 13 in phase 1, and was the 10th registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →6 of the 36 studies in Pneumococcal Infections with a site in China are open now. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
CanSino Biologics Inc. · Sites in China
Ages 6 wk+ · Healthy volunteers
Sinovac Life Sciences Co., Ltd. · Sites in China
Ages 42 days–5 yrs · Healthy volunteers
Sinovac Life Sciences Co., Ltd. · Sites in China
Ages 42 days–23 mo · Healthy volunteers
Sinovac Life Sciences Co., Ltd. · Sites in China
Ages 6 wk–5 yrs · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 6 Weeks and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 5 · Phase 3 9 · Phase 4 6
First in 2007; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 237 is below the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 480 across the 33 interventional studies, 3,641 across the 3 observational. Of the 26 that completed or were terminated, 4 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 36 have an industry lead sponsor. The 10 most frequent:
CanSino Biologics Inc. is the lead sponsor of 41 studies on the registry; 6 are open to participants now.
CanSino Biologics Inc. has 5 studies filed under Pneumococcal Infections — fewer than ten, so there is no comparison to draw.
2 of the studies in Pneumococcal Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07600983CanSino Biologics Inc.Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) | 2026-11-24 |
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Pneumococcal Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Streptococcus pneumoniae is a major cause of morbidity and mortality in children worldwide, resulting in up to 1 million pediatric deaths every year.Since the licensure of PCV7 and PCV13,the reported overall decline in invasive pneumococcal disease in hospitalized children younger than 5 years several years is approximately 60% in Western countries.This is a single center,blind, randomized, positive-controlled clinical trial.The purpose of this study is to preliminary evaluate the safety of PCV13i vaccine in subjects at age of 7 months and above,and to investigate the safety and immunogenicity of PCV13i vaccine at age of 2 and 3 months,compared to PCV13.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received one dose of PCV13i at 18 to 49 years old
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)
Subjects received one dose of PCV13i at 50 years old and above
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)
Subjects received one dose of PCV13i at 6 to 17 years old
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)
Subjects received one dose of PCV13i at 2 to 5 years old
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)
Subjects received two doses of PCV13i at 7 months to 2 years old
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)
Subjects received three doses of PCV13i at 3,4,5 months of age
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)
Subjects received three doses of PCV13i at 2,4,6 months of age
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)
Subjects received three doses of PCV13 at 2,4,6 months of age
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
0.5mL,Intramuscular other name:PCV13i
0.5mL,Intramuscular other name:Prevnar
Safety items of adverse reactions
Occurrence of adverse reactions of each subject(Arm 1A-7B)
Time frame: within 7 days post each vaccination
Safety items of SAE
Occurrence of SAE of each subject(Arm 1A-7B)
Time frame: within 6 months post last vaccination
Safety items of Hematological examination
Occurrence of abnormal changes of Hematological examination in subjects of 2 years old and above(Arm 1A-4A)
Time frame: day 4 post vaccination
Safety items of Urine test
Occurrence of abnormal changes of Urine test in subjects of 2 years old and above(Arm 1A-4A)
Time frame: day 4 post vaccination
Safety items of Blood chemistry test
Occurrence of abnormal changes of Blood chemistry test in subjects of 2 years old and above(Arm 1A-4A)
Time frame: day 4 post vaccination
Safety items of pressure value
Occurrence of abnormal changes of pressure valus in subjects of 18 years old and above(Arm 1A-2A)
Time frame: day 4 post vaccination
Safety items of heart rate
Occurrence of abnormal changes of heart rate in subjects of 18 years old and above(Arm 1A-2A)
Time frame: day 4 post vaccination
Safety items of adverse reactions
Occurrence of adverse reactions of each subject(Arm 1A-7B)
Time frame: within 30 days post each vaccination
immunogencity items of seropositivity rates by ELISA
Serotype-specific seropositivity rates of Immunoglobulin G concentrations above 0.35ug/ml in subjects aged 2 and 3 months post last vaccination(Arm 6A-7B)
Time frame: day 30 post last vaccination
immunogencity items of GMC by ELISA
Serotype specific IgG GMC of each the pneumococcal serotypes in subjects aged 2 and 3 months post last vaccination(Arm 6A-7B)
Time frame: day 30 post last vaccination
immunogencity items of GMI by ELISA
Serotype-specific GMI value pneumococcfor each of the pneunococcal serotypes in subjects aged 2 and 3 months post last vaccination(Arm 6A-7B)
Time frame: day 30 post last vaccination
immunogencity items of GMT
Serological response in terms of GMT for each of the pneumococcal serotypes tested by OPA in subjects aged 2 months post last vaccination(7A、7B)
Time frame: day 30 post last vaccination
Plan to share: No — In order to maintain the rights of the subject, do not open the IPD
No publications or documents are linked to this record.
Ran from May 2020 to primary completion in Jun 2021, 13 months.
Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 13 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.